Clostridium Butyricum miyairi bacteriocin treatment for Clostridioides difficile infections with clinical isolates: Insights from in vitro, ex vivo, and mouse model studies

Clostridium Butyricum miyairi bacteriocin treatment for Clostridioides difficile infections with clinical isolates: Insights from in vitro, ex vivo, and mouse model studies

Objective: The standard antimicrobial therapy for Clostridioides difficile infections (CDIs) is limited to oral fidaxomicin or vancomycin, but these agents are associated with high treatment failure and recurrence rates. Clostridium butyricum has been proven effective in many types of gastrointestin...

Full description

Saved in:
Bibliographic Details
Main Authors: Ching-Chi Lee, Yi-Chen Tu, Hung-Tsung Wu, Wen-Chien Ko, Hsiao-Chieh Liu, Pei-Jane Tsai, Hsiang-Ning Chang, I-Hsiu Huang, Yuan-Pin Hung
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:Journal of Global Antimicrobial Resistance
Subjects:
Clostridium butyricum
Bacteriocin
Clostridioides difficile infection
Susceptibility
Minimal inhibitory concentration
Online Access:http://www.sciencedirect.com/science/article/pii/S2213716525000669
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items